earnings
confidence high
sentiment positive
materiality 0.85
Alnylam Q1 product rev $469M (+28% YoY); AMVUTTRA approved for ATTR-CM; guides FY25 $2.05-2.25B
ALNYLAM PHARMACEUTICALS, INC.
2025-Q1 EPS reported
-$0.44
revenue$594,189,000
- Q1 total revenues $594M, up 20% YoY; GAAP operating income $18M vs loss of $43M in Q1 2024.
- Q1 global net product revenues $469M, 28% growth YoY; hATTR-PN franchise grew 36%.
- AMVUTTRA (vutrisiran) received FDA approval for ATTR-CM; launch underway with early progress.
- Qfitlia (fitusiran) approved by FDA for hemophilia A/B, sixth Alnylam-discovered RNAi therapeutic.
- Reiterated FY2025 combined net product revenue guidance of $2.05B-$2.25B.